JP7451520B2 - ヒト化抗ＳＩＲＰα抗体 - Google Patents

ヒト化抗ＳＩＲＰα抗体 Download PDF

Info

Publication number
JP7451520B2
JP7451520B2 JP2021526658A JP2021526658A JP7451520B2 JP 7451520 B2 JP7451520 B2 JP 7451520B2 JP 2021526658 A JP2021526658 A JP 2021526658A JP 2021526658 A JP2021526658 A JP 2021526658A JP 7451520 B2 JP7451520 B2 JP 7451520B2
Authority
JP
Japan
Prior art keywords
antibody
sirpα
amino acid
antibodies
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509065A (ja
JP2022509065A5 (https=
Inventor
フェルヘイデン、ヘイスベルトゥス・フランシスクス・マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Byondis BV
Original Assignee
Byondis BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis BV filed Critical Byondis BV
Publication of JP2022509065A publication Critical patent/JP2022509065A/ja
Publication of JP2022509065A5 publication Critical patent/JP2022509065A5/ja
Application granted granted Critical
Publication of JP7451520B2 publication Critical patent/JP7451520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021526658A 2018-11-15 2019-11-15 ヒト化抗ＳＩＲＰα抗体 Active JP7451520B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18206594 2018-11-15
EP18206594.6 2018-11-15
PCT/EP2019/081523 WO2020099653A1 (en) 2018-11-15 2019-11-15 HUMANIZED ANTI-SIRPα ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2022509065A JP2022509065A (ja) 2022-01-20
JP2022509065A5 JP2022509065A5 (https=) 2022-11-02
JP7451520B2 true JP7451520B2 (ja) 2024-03-18

Family

ID=64331834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526658A Active JP7451520B2 (ja) 2018-11-15 2019-11-15 ヒト化抗ＳＩＲＰα抗体

Country Status (13)

Country Link
US (1) US12180295B2 (https=)
EP (1) EP3880707A1 (https=)
JP (1) JP7451520B2 (https=)
CN (1) CN113412279B (https=)
AU (1) AU2019378101B2 (https=)
BR (1) BR112021009275A2 (https=)
CA (1) CA3118966A1 (https=)
CL (1) CL2021001260A1 (https=)
IL (1) IL282756A (https=)
MX (1) MX2021005761A (https=)
MY (1) MY204673A (https=)
SG (1) SG11202104431PA (https=)
WO (1) WO2020099653A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL262251B2 (en) 2016-04-14 2023-09-01 Ose Immunotherapeutics New anti-syrap antibodies and their medical applications
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
KR102702926B1 (ko) * 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
JP7337099B2 (ja) 2018-05-25 2023-09-01 アレクトル エルエルシー 抗ｓｉｒｐａ抗体およびその使用法
AU2021378152A1 (en) * 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
TW202317620A (zh) 2021-06-04 2023-05-01 德商百靈佳殷格翰國際股份有限公司 抗ＳＩＲＰα抗體
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512487A (ja) 2012-12-26 2016-04-28 オンコシナジー インコーポレイテッド 抗インテグリンβ１抗体組成物及びその使用方法
WO2017178653A2 (en) 2016-04-14 2017-10-19 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
WO2018057669A1 (en) 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
JP2020520370A (ja) 2017-05-16 2020-07-09 ビョンディス・ビー．ブイ．Ｂｙｏｎｄｉｓ Ｂ．Ｖ． 抗ＳＩＲＰα抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
BR112013031762A2 (pt) * 2011-06-16 2016-09-13 Novartis Ag proteínas solúveis para utilização como terapêuticos
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
CN106456749B (zh) * 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
PL3180363T3 (pl) * 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
CN114425077A (zh) 2015-05-18 2022-05-03 起源生物医药公司 Sirp多肽组合物和使用方法
WO2017068164A1 (en) 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
AU2017371070B2 (en) * 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512487A (ja) 2012-12-26 2016-04-28 オンコシナジー インコーポレイテッド 抗インテグリンβ１抗体組成物及びその使用方法
WO2017178653A2 (en) 2016-04-14 2017-10-19 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
WO2018057669A1 (en) 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
JP2020520370A (ja) 2017-05-16 2020-07-09 ビョンディス・ビー．ブイ．Ｂｙｏｎｄｉｓ Ｂ．Ｖ． 抗ＳＩＲＰα抗体

Also Published As

Publication number Publication date
JP2022509065A (ja) 2022-01-20
US12180295B2 (en) 2024-12-31
SG11202104431PA (en) 2021-05-28
US20210388107A1 (en) 2021-12-16
EP3880707A1 (en) 2021-09-22
CN113412279A (zh) 2021-09-17
MX2021005761A (es) 2021-08-11
BR112021009275A2 (pt) 2022-01-04
IL282756A (en) 2021-06-30
CA3118966A1 (en) 2020-05-22
CL2021001260A1 (es) 2021-12-24
AU2019378101B2 (en) 2025-10-16
CN113412279B (zh) 2024-09-24
MY204673A (en) 2024-09-09
WO2020099653A1 (en) 2020-05-22
KR20210093270A (ko) 2021-07-27
AU2019378101A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP7451520B2 (ja) ヒト化抗ＳＩＲＰα抗体
US12258410B2 (en) Anti-SIRPα antibodies and methods of use thereof
EP3625259B1 (en) Anti-sirpalpha antibodies
US20230192847A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
US20260098089A1 (en) Antagonist anti-cd7 antibodies
CN112384532B (zh) 抗SIRP-β1抗体及其使用方法
US20190330351A1 (en) Anti-pd-l1 antibodies
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
TW202221029A (zh) 抗cd93之構築體及其用途
TW202325735A (zh) 特異性結合ｃｄ４７及ｃｄ２０之雙特異性抗體及其用途
US20240165227A1 (en) Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
KR102955590B1 (ko) 인간화 항-SIRPα 항체
RU2812199C2 (ru) ГУМАНИЗИРОВАННЫЕ АНТИ-SIRPα АНТИТЕЛА
US12521446B2 (en) Anti-CEACAM5 antibody drug conjugates
US20260115307A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
WO2026096695A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
WO2025184208A1 (en) Anti-ceacam5 antibodies and uses thereof
TW202210515A (zh) 抗ｃｄ３９之構築體及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221025

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240306

R150 Certificate of patent or registration of utility model

Ref document number: 7451520

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150